Implementing an Innovative Lipid Management Technique Using siRNA LDL-C Lowering Therapy: Lessons Learned in an NHS Primary Care Practice With Worked Case Examples.

Introduction: The UK Government partnered with industry to tackle cardiovascular disease (CVD) in the first NHS population health agreement. The ambition was to prevent 150 000 strokes, heart attacks and dementia cases over the next 10 years with a new siRNA LDL-C lowering therapy (Inclisiran) delivered within Integrated Care Services by primary care to support a comprehensive approach to lipid management. Following the approval of inclisiran, and guidance published by the National Institute for Health & Care Excellence (NICE) on its use, this paper has been created by a UK general practice to share real-world observations of cases and the potential service benefits of rolling out this innovative drug treatment.

The Translation of Movement From the Equine to Rider With Relevance for Hippotherapy.

Although horseback riding is a well-established means of rehabilitation therapy for a variety of human patients, there are few data on the biomechanical relationships between horse and rider during such hippotherapy. We simultaneously tracked the movements of a horse with several different novice riders, under conditions similar to hippotherapy, to evaluate whether horses pass the same motion to different riders while being lead at a walk. Riders were outfitted with a goniometric data collection system that recorded the angles of flexion and extension and lateral bending of the thoracic and lumbar spine, as well as the flexion, extension, abduction, and adduction of each hip.